Gastroesophageal Reflux Disease Linked to GLP-1 Receptor Agonists: A Multi-Country Drug Safety Analysis

Gastrointestinal adverse events are common in patients using glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for type 2 diabetes and obesity.

• The relationship between GLP-1 RAs and gastroesophageal reflux disease (GERD) has not been previously validated in diverse populations.
• Disproportionality analysis was conducted using three national adverse event reporting systems to assess GERD signals.
• Findings may indicate a need for further investigation into the safety profile of GLP-1 RAs concerning GERD.

Simplified